Prostate Cancer - Results from #1020

REVIEW UroToday

Beyond the Abstract - Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): A new risk factor for prostate cancer, by Bimal Bhindi August 10, 2012

Beyond the Abstract - Distinct redox profiles of selected human prostate carcinoma cell lines: Implications for rational design of redox therapy, by Luksana Chaiswing, PhD August 9, 2012

Beyond the Abstract - Patients aged more than 70 had higher risk of locally advanced prostate cancers and biochemical recurrence in Korea, by Jung Kwon Kim and Sung Yong Cho August 7, 2012

Beyond the Abstract - In vivo versus in vitro individual radiosensitivity analysed in healthy donors and in prostate cancer patients with and without severe side effects after radiotherapy, by Michael Pinkawa, MD, PhD August 6, 2012

Beyond the Abstract - Proof-of-concept study of monitoring cancer drug therapy with Cerenkov luminescence imaging, by Yingding Xu and Zhen Cheng August 3, 2012

Beyond the Abstract - Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term, by James W. Denham, MD, FRANZCR August 3, 2012

Beyond the Abstract - Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells, by Przemyslaw Twardowski, MD and C.A. Stein, MD, PhD August 2, 2012

Beyond the Abstract - The language of prostate cancer treatments and implications for informed decision making by patients and their partners, by Richard Wassersug, PhD August 2, 2012

Beyond the Abstract - Treatment of bone metastasis in prostate cancer: Efficacy of a novel polybisphosphonate, by Anders R. Holmberg, PhD, DMSc August 1, 2012

Beyond the Abstract - Variations in the exome of the LNCaP prostate cancer cell line, by Lien Spans, et al July 27, 2012

Beyond the Abstract - Biexponential diffusion decay in formalin-fixed prostate tissue: Preliminary findings, by Roger Bourne, PhD July 26, 2012

Beyond the Abstract - Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies, by Boris Gershman, MD and W. Scott McDougal, MD July 25, 2012

Beyond the Abstract - Prostate-cancer mortality at 11 years of follow-up, by Fritz H. Schröder, MD July 24, 2012

Beyond the Abstract - Urinary morbidity after permanent prostate brachytherapy - Impact of dose to the urethra vs. sources placed in close vicinity to the urethra, by Michael Pinkawa, MD July 23, 2012

Beyond the Abstract - Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer, by Tsutomu Nishiyama, MD, PhD July 19, 2012

Beyond the Abstract - Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases, by Jipan Xie, MD, PhD July 18, 2012

Beyond the Abstract - An update on the changing indications for androgen deprivation therapy for prostate cancer, by Dan Arnett, Megan Griffiths, Mike Glode, and Shandra Wilson July 16, 2012

Beyond the Abstract - Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer, by Kanishka Sircar, MD, Nora Navone, MD, PhD, Wei Zhang, PhD, and Nigel Richards, PhD July 12, 2012

Beyond the Abstract - Androgen receptor co-activators in the regulation of cellular events in prostate cancer, by Zoran Culig and Frédéric R. Santer July 12, 2012

Beyond the Abstract - Patients and partners lack knowledge of androgen deprivation therapy side effects, by Susan Tran, BA (Hons), et al July 10, 2012

Page 52 of 57